FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

STATISTICS AND MEDICINE Previous Volume 356:1705-1707 April 26, 2007 Number 17 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Perspective Perspective by The DAD Study Group Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by The DAD Study Group PubMed Citation

In this issue of the Journal, Friis-Møller and colleagues (pages 1723–1735) report on results from a prospective observational study involving more than 23,000 patients infected with HIV. The study, called the Data Collection on Adverse Effects of Anti-HIV Drugs (DAD) trial, identified a possible increased risk of myocardial infarction associated with exposure to protease inhibitors but not to nonnucleoside reverse-transcriptase inhibitors. Because randomized studies are rarely well powered for evaluating adverse effects of treatment, well-designed observational studies are important.¹ However, such studies raise complex questions concerning both the potential confounding of risk associations and the mechanisms by which treatment might . . . [Full Text of this Article]

Source Information

Dr. Hughes is a professor and Dr. Williams a senior lecturer in the Center for Biostatistics in AIDS Research at the Harvard School of Public Health, Boston.

Related Letters:

Antiretroviral Drugs and the Risk of Myocardial Infarction
Kaplan R. C., Tien P. C., Lazar J., Zangerle R., Sarcletti M., Pollack T. M., Rind D. M., Sabin C., Friis-Møller N., Lundgren J. D., the Writing Committee of the DAD Study Group , Stein J. H.
Extract | Full Text | PDF  
N Engl J Med 2007; 357:715-717, Aug 16, 2007. Correspondence

This article has been cited by other articles:

• Schambelan, M., Wilson, P. W.F., Yarasheski, K. E., Cade, W. T., Davila-Roman, V. G., D'Agostino, R. B. Sr, Helmy, T. A., Law, M., Mondy, K. E., Nachman, S., Peterson, L. R., Worm, S. W., for Working Group 5, (2008). Development of Appropriate Coronary Heart Disease Risk Prediction Models in HIV-Infected Patients. Circulation 118: e48-e53 [Full Text]  
• Shermock, K. M., Horn, E., Rice, T. L. (2008). Erythropoietic agents for anemia of critical illness. Am J Health Syst Pharm 65: 540-546 [Abstract] [Full Text]  
• Kaplan, R. C., Tien, P. C., Lazar, J., Zangerle, R., Sarcletti, M., Pollack, T. M., Rind, D. M., Sabin, C., Friis-Moller, N., Lundgren, J. D., the Writing Committee of the DAD Study Group, , Stein, J. H. (2007). Antiretroviral drugs and the risk of myocardial infarction.. NEJM 357: 715-716 [Full Text]  
• (2007). Long-Term ART and Risk for Myocardial Infarction. JWatch Infect. Diseases 2007: 1-1 [Full Text]  
• (2007). Antiretroviral Therapy and Cardiovascular Disease. AIDS Clin Care 2007: 1-1 [Full Text]